Search Results
Teprotumumab-related adverse events common but mild
Most adverse events (AEs) in patients with thyroid eye disease (TED) treated with teprotumumab are common but most are mild...
Read MoreHow did pandemic-related teprotumumab treatment delays impact outcomes?
During the COVID-19 pandemic, the production of teprotumumab was interrupted to divert resources to government-mandated vaccine production resulting in some...
Read MoreHealthcare resource utilization high among patients with TED
Healthcare resource utilization (HRU) was high among patients with thyroid eye disease (TED) treated with steroids and/or surgery, according to...
Read MoreStudy first to examine TED manifestations in Black, Hispanic populations
In the first study to examine manifestations and severity of thyroid eye disease (TED) in a primarily Black and Hispanic...
Read MoreTeprotumumab increases tear production in patients with TED
Patients with thyroid eye disease (TED) treated with teprotumumab had significant reductions in the volume of lacrimal glands as well...
Read MoreTeprotumumab retreatment beneficial for TED patients with insufficient initial response
Patients with thyroid eye disease (TED) who do not respond to initial treatment with teprotumumab may benefit from additional teprotumumab...
Read MoreErin Shriver
Erin Shriver, MD, FACS is a Clinical Professor and the Jim O’Brien Gross and Donnita Gross Chair in Ophthalmology within...
Read MoreMycophenolate mofetil appears to be effective second-line treatment for TED
Mycophenolate mofetil (MMF) appears safe and effective as a second-line immunosuppressive agent in patients with thyroid eye disease (TED), according...
Read MoreTeprotumumab improves clinical course of TED
The clinical course of thyroid eye disease (TED) was improved with the treatment of teprotumumab in all patient subgroups, according...
Read MoreStudy: Significant QOL improvements for patients with TED
In a recent study that evaluated the compassionate use of teprotumumab demonstrated large quality of life (QOL) improvements. The results...
Read MoreStudy: Teprotumumab improves symptoms of TED
Results from a recent study using teprotumumab in the treatment of thyroid eye disease (TED) support previously reported improvements in...
Read MoreTherapeutic contact lens use yields improved vision in patients with TED
Therapeutic contact lenses, including soft and scleral lenses, were associated with visual improvement in a study of patients with thyroid...
Read MoreWhat is a Rainbow Brow?
In a presentation at ARVO 2021, Emery Jamerson, MD, described “Rainbow Brow”- a novel physical exam finding in patients with...
Read More
Contact Info
